Dtablet raises NOK 4 million seed round from angel investors

Dtablet Closes Seed Round

Dtablet, a Norwegian health-technology startup, has raised a seed round of NOK 4,000,000. The round was backed by a group of angel investors: Thomas Ulleberg, Carl-André Nørstebø, Kim Frode Solheim, Jostein Sylta, Bjørn Åge Brandal and Hallgrim Bjørvik. No lead investor was designated.

What the Company Does

Dtablet is developing Dtablet Week, a smart pill organizer paired with a companion app. The system reminds users to take their medication, logs doses and adapts to the user's daily routine.

The hardware is a seven-compartment, lockable pillbox that adds biometric unlock, caretaker notifications and location tracking. The design intent is to make everyday medication management simpler and less stigmatizing for users.

Founder Background

Dtablet was founded by CEO Hallgrim Bjørvik, who previously helped build the technology and design agency Increo before its 2025 exit. That background in technology and design is relevant to a product category where user experience and adherence are central to adoption.

Stage and Next Steps

The company is preparing Dtablet Week for mass production and launch. The seed funding arrives at the pre-production stage, a point where hardware startups typically face tooling, manufacturing and regulatory costs before revenue begins.

Deal Context

• Company: Dtablet
• Sector: Health technology / medication management
• Stage: Seed
• Amount: NOK 4,000,000
• Investors: Thomas Ulleberg, Carl-André Nørstebø, Kim Frode Solheim, Jostein Sylta, Bjørn Åge Brandal, Hallgrim Bjørvik
• Lead investor: None designated
• Funding date: October 23, 2026
• Location: Norway

Why It Matters for Acquisition Watchers

Medication adherence is a persistent problem for health systems, insurers and care providers, and hardware-plus-app solutions that generate adherence data can be strategically valuable beyond the consumer device itself. Dtablet's combination of biometric locking, caretaker notifications and location tracking positions it in the assisted-living and chronic-care segments as much as the direct-to-consumer market.

The all-angel investor list, including the founder, indicates an early, relationship-driven round rather than institutional backing. That structure often precedes a larger venture round once manufacturing and launch milestones are met.

For strategic buyers in home health, pharmacy services or connected medical devices, Dtablet is an early-stage asset with a defined product and an imminent production phase. The key diligence questions will center on manufacturing readiness, unit economics and the regulatory classification of the device in its target markets.

What to Watch

• Progress toward mass production of Dtablet Week
• Launch timing and initial market geography
• Evidence of adherence outcomes and user retention
• Whether the company raises institutional capital after launch